Boehringer Ingelheim Press Releases

The third "European Porcine Circovirus Research Award" honours scientists from Spain and Denmark

Boehringer Ingelheim announces its intention to acquire all the outstanding shares in SSP Co., Ltd. ("SSP") through a tender offer

Metacam® receives EU approval for the relief of pain in castrated piglets

Boehringer Ingelheim and Priaxon announce a collaboration to research and develop novel treatments for cancer

Largest pig producing country China approves novel vaccine against widespread pig disease

Boehringer Ingelheim initiates first Phase III clinical trial in Ovarian Cancer

Milestone results in RE-COVER™ study – novel oral direct thrombin inhibitor dabigatran etexilate – as effective as well controlled warfarin with less bleeding in treatment of acute venous thromboembolism

Milestone results assessing novel anticoagulation dabigatran etexilate versus warfarin in the treatment of acute deep vein thrombosis and pulmonary embolism to be presented at ASH 2009

Major European regulatory milestone in cardiovascular protection for Micardis® (telmisartan): Now approved by the European Commission to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients

Boehringer Ingelheim and Vectura conclude collaboration

Boehringer Ingelheim and GlaxoSmithKline back EFA`s call for urgent improvements in care for people with lung disease this World COPD Day

Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder (HSDD)

Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX technology platform

Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products

Boehringer Ingelheim Animal Health closes deal to acquire a significant portion of the Fort Dodge Animal Health Business from Pfizer

CHMP issues positive opinion for Micardis® (telmisartan) as the first treatment in its class to reduce the risk of cardiovascular (CV) morbidity in high CV risk patients

FDA approves Twynsta® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

FDA approves Micardis® (telmisartan) as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors